Dataset opportunity
Endiatx — 医疗影像数据集机会
由 Endiatx 持有的中等规模医疗影像数据集，可用于诊断AI和计算机视觉。
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球医疗影像AI市场：2024年为17.0亿美元，预计到2034年将达到168.8亿美元，复合年增长率（2025-2034）为25.8%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-05
J&J, Medtronic back CereVasc’s $85M funding round
medtechdive.com ↗ - 📰press2026-06-05
Olympus’ Keith Boettiger on robotic GI surgery push
medtechdive.com ↗ - 📰press2026-06-05
Dexcom buys Nutrisense; Insulet rolls out patch pump update
medtechdive.com ↗ - 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
More Americans own wearables, connected health devices: survey
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗AI和诊断影像公司
Endiatx 拥有宝贵的医学影像数据集（特别是影像模态），源自诊断程序，并得到了相关的物联网数据和全面的医疗记录的显著增强，贡献了强大的数据量。这个丰富的数据集非常适合训练和验证先进的诊断人工智能模型，从而提高医学诊断的准确性和效率。
医学影像人工智能市场展现出巨大的商业价值，预计市场规模从 2024 年的17 亿美元增长到 2034 年的168.8 亿美元，复合年增长率 (CAGR) 高达 25.8%。尽管由于FDA 批准要求、严格的患者隐私顾虑（HIPAA/GDPR 等效）以及二次使用需要明确的患者同意，以及由于持续的临床试验导致商业数据量有限，存在固有的访问复杂性，但这种高质量的医疗数据仍然受到诊断人工智能买家的追捧。其稀缺性和革新诊断的潜力使其成为一个快速扩张市场中的关键资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：商业使用该设备需要 FDA 批准，这会影响数据生成量和可访问性；由于是高度敏感的医学影像数据，存在患者隐私（HIPAA/GDPR 等效）顾虑；数据是在诊断过程中生成的，可能需要患者明确同意任何二次使用；目前处于临床试验阶段，因此在全面上市之前，商业生成的数据量有限。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Endiatx 持有其创新的 PillBot 机器人胶囊直接从胃部捕获的专有且极其稀有的实时高清视频数据集。这种独特的医学影像数据正是诊断人工智能和医学影像公司开发突破性胃肠道分析解决方案所需要的。它代表了在预计从 2024 年的 17 亿美元增长到 2034 年的 168.8 亿美元的市场中推动医学影像人工智能发展的关键资产，目前提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的“医疗记录”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume68
3 个证据命中，明确提及数据量
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
医学影像人工智能市场，高度依赖这些数据集，2022 年估值为 13.8 亿美元，预计 2023 年至 2032 年的复合年增长率将超过 30.5%，表明买家需求极高且不断增长。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=已拥有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据需求信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5 个近期外部信号 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ 良好目标 — Endiatx 是一家医疗机器人公司，正在开发一种诊断设备（PillBot），该设备作为其核心业务的副产品生成有价值的、小众的、专有的医学影像数据，使其成为数据市场的良好目标，尽管有提供数据服务的意向。问题：Endiatx 已表示有意在其生态系统中提供“数据服务”，这可能演变为销售数据或智能业务的核心业务；员工咨询
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该证据证实 Endiatx 从其 PillBot 生成实时高清视频，提供独特的体内成像数据，这对于训练用于胃肠道疾病的先进诊断人工智能模型至关重要。
IoT / sensor data
这表明 Endiatx 拥有来自 PillBot 的多模态运营数据，包括其运动和远程控制的时间序列数据，这对于理解设备性能和为人工智能开发提供视觉数据背景至关重要。
Data-volume signal
PillBot 1.0 的持续临床试验和 PillBot 2.0 的开发证实了持续且不断扩大的多模态数据生成管道，确保了高质量、真实世界数据量的不断增长，用于长期人工智能模型优化。
Marketplace
Dataset details
Geographic coverage
Global
Time range
Real-time
Update frequency
Real-time
Delivery
API
Formats
Video, JSON
License
One-time license for AI model training and validation in diagnostic applications.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This dataset's value is driven by its high rarity as proprietary, real-time, in-stomach video from a robotic capsule, coupled with significant demand from the rapidly growing AI in Medical Imaging market. The unique modality and potential for diagnostic AI development justify a premium valuation.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Endiatx Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = US$ 1.70 billion in 2024, projected to reach US$ 16.88 billion by 2034, growing at a CAGR of 25.8% (2025-2034).. Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Greentech — 维护日志数据集机会
View opportunity →工业Nuday — 工业传感器数据集机会
View opportunity →其他Greenhousedatacenters — 传感器遥测数据集机会
View opportunity →